Iron Preparations Research Articles (Page 1)

Abstract Background and Aims Anaemia of chronic kidney disease (CKD) is a major unmet medical need. Vadadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), approved for the treatment of anaemia of dialysis-dependent CKD, stimulates endogenous erythropoietin (EPO) production, increasing haemoglobin (Hb) and haematocrit (HCT). Ferric citrate is a source of iron and is used as a treatment for iron deficiency anaemia. The objectives of these studies were to determine if the co-administration of vadadustat with a well-absorbed oral iron preparation such as ferric citrate would have additive effects on anaemia correction. Method The experiments were conducted in the peptidoglycan polysaccharide (PGPS) rat model of inflammation-induced anaemia, and the rat model of adenine-induced CKD (n = 10/group). Primary treatments included both vadadustat and ferric citrate alone and in combination, with appropriate controls. Recombinant human EPO (rhEPO) was used in some experiments as a comparator. Results In the PGPS rat model of inflammation-induced anaemia, the coadministration of vadadustat and ferric citrate caused a statistically significant increase in serum iron and transferrin saturation (TSAT) and a statistically significant decrease in total iron binding capacity (TIBC) compared to when vadadustat or ferric citrate were given alone. There were also increases in Hb, HCT, percent reticulocytes, mean corpuscular volume (MCV) and mean corpuscular haemoglobin (MCH) levels. Regarding inflammation, the combination of vadadustat and ferric citrate treatment decreased white blood cell counts in a statistically significantly manner and this was associated with decreases in neutrophil and lymphocyte counts, haptoglobin, IL-6, IL-15, C-reactive protein, ankle diameter and paw weight. Similarly, in the rat model of adenine-induced CKD, there was a statistically significant increase in serum iron levels in the rats given vadadustat in combination with ferric citrate compared to the rats given ferric citrate or vadadustat alone or in rats given rhEPO either alone or in combination with ferric citrate. Consistent with the serum iron data, the combination of vadadustat and ferric citrate resulted in increases in TIBC, serum iron saturation percent, Hb, HCT, MCV and MCH levels. Serum levels of IL-6, FGF-21, and myostatin, markers of inflammation, did not differ statistically across groups. Conclusion Collectively, these data suggest vadadustat in combination with oral iron provides greater improvement in anaemia related parameters in models of inflammation-induced anaemia and CKD than when either agent is given alone.

ObjectivesThis study has two primary objectives: (a) to conduct a comparative cost-effectiveness analysis of four commonly used oral iron supplements for treating iron-deficiency anemia during pregnancy in China, including ferrous succinate sustained-release tablets, polysaccharide-iron complex capsules, iron protein succinylate oral solution, and iron dextran oral solution; and (b) to assess the budget impact of including ferrous succinate sustained-release tablets in the National Reimbursement Drug List (NRDL) on national medical insurance expenditures.MethodsA decision tree model was developed to analyze the cost-effectiveness based on treatment efficacy derived from a network meta-analysis. A sensitivity analysis was conducted to address uncertainties in the parameters. Subsequently, a budget impact analysis model was utilized to calculate the effect of including ferrous succinate sustained-release tablets in the NRDL on the expenditures of employee medical insurance funds, resident medical insurance funds, and the total medical insurance fund expenditures.ResultsThe cost-effectiveness analysis showed that ferrous succinate sustained-release tablets are a cost-effective treatment option. When compared to polysaccharide-iron complex capsules, the additional cost per effect of the ferrous succinate sustained-release tablets is $3.23. If these tablets are included in the NRDL, the total medical insurance expenditure on oral iron preparations for treating iron-deficiency anemia in pregnant women is expected to decrease from $160.14 million to $156.82 million between 2025 and 2027.ConclusionFerrous succinate sustained-release tablets are a cost-effective treatment option for iron-deficiency anemia during pregnancy in China.

Aim:This study aimed to assess the impact of oral Fe+2 iron preparations on weight, body composition, metabolic, and appetite parameters in adults undergoing treatment for iron deficiency.Methods:In this observational prospective study, a total of 119 patients, aged 18–45, initiating Fe+2 iron therapy for iron deficiency within the last month at Family Medicine Outpatient Clinic, were included. Data on sociodemographic variables, health, dietary habits, anthropometric measurements, metabolic parameters, and appetite scores were collected. The Power of Food (PFS), Visual Analogue Scale (VAS), and Three-Factor Eating Questionnaire (TFEQ) were utilized for appetite assessment.Findings:After three months of iron treatment, a statistically significant increase was found in the mean values of Hb, Hct, MCV, ferritin, iron, and transferrin saturation; anthropometric measurements displayed a significant reduction in body weight, body mass index (BMI), fat percentage, waist circumference, hip circumference, and waist/hip circumference ratios post-treatment. Notably, VAS scores for certain food items decreased, while carbonated drinks VAS score increased. Appetite-related factors, as per PFS, exhibited a significant decrease in PFS factor 1 (food available), PFS factor 2 (food present).Conclusions:In conclusion, our findings indicate that oral Fe+2 iron preparations positively influence the treatment of iron deficiency anaemia by improving haematological parameters and concurrently leading to a significant reduction in body weight, BMI, and appetite scores related to specific food items. The study underscores the multifaceted impact of iron supplementation on both physiological and behavioural aspects, providing valuable insights for optimizing iron deficiency anaemia management.

Iron deficiency and iron deficiency anemia (IDA) are prevalent during infancy. Timely iron prophylaxis can prevent associated irreversible complications. As part of the "Iron Like Turkey" program initiated in April 2004, iron prophylaxis is administered from the fourth month of life for at least 5 months. This study aims to evaluate the implementation of iron prophylaxis in our country and compare the effectiveness of different iron preparations used in prophylaxis. Between January 2021 and January 2024, the iron prophylaxis status of 248 healthy, full-term, breastfed infants 9 to 15 months old who were referred to the Pediatric Hematology outpatient clinic of Manisa City Hospital for various reasons was assessed. Iron prophylaxis was administered to 204 (82.3%) infants, of whom 92 (44.1%) had irregular usage. Among those receiving iron prophylaxis, 110 (53.9%) used Fe+3, while 94 (46.1%) used Sucrosomial Iron (SI). No infants received Fe+2 for prophylaxis. Iron deficiency anemia (IDA) was present in 142 (57.3%) cases. No significant difference was found between Fe+3and Sucrosomial Iron in terms of adherence and duration of prophylaxis (P>0.05). However, hemoglobin (Hb), mean corpuscular volume (MCV), ferritin, and transferrin saturation levels were significantly lower in the Sucrosomial Iron group compared with the Fe+3 group (P<0.05). Iron prophylaxis is an easy and effective method to prevent IDA. Both mothers during pregnancy and infants should receive prophylaxis on time and for an adequate duration. Further research is needed to evaluate the efficacy of different iron formulations used in prophylaxis.

Aim. To describe the immediate and long-term results of a series of cases of the use of epoetin alfa in preoperative therapy of malignant tumors of the female reproductive system, performed at a single clinical center.Materials and methods. The article presents the experience of treating anemia (2–3 degrees of severity) of various origins with erythropoiesis-stimulating drugs in monotherapy or in combination with iron preparations in 5 patients who sought medical care at the Federal Research and Clinical Center for Specialized Medical Care and Medical Technologies, Federal Biomedical Agency of the Russian Federation for the period from August 2024 to February 2025 due to malignant tumors of the female reproductive system of various localizations, for whom surgical treatment was indicated.Results. The mean age of patients at the time of surgery was 55.4 ± 32.5 years. The mean body mass index of patients was 25.6 ± 1.6. The mean hemoglobin level in the blood at the time of diagnosis was 78.2 ± 3 g / L. The mean duration of preoperative drug therapy was 4.4 ± 1.5 weeks, during which 2 (40 %) patients received monotherapy with epoetin alfa (40,000 IU once a week subcutaneously), 3 (60 %) patients with serum ferritin &lt;100 ng / ml and serum transferrin iron saturation &lt;20 % – combination therapy in combination with iron [III] hydroxide sucrose complex (intravenous jet stream 200 mg 3 times a week). The mean hemoglobin level at the time of surgery was 102.2 ± 8.5 g / L. The average postoperative hospital stay was 7.2 ± 5.5 days. No intra- or perioperative complications were observed. The average postoperative follow-up period was 7 (3–9) months, during which no recurrence of the disease was detected (0 %).Conclusion. The correction of multifactorial anemia of 2–3 degrees of severity in the preoperative period in malignant tumors of the female reproductive system using erythropoietins in monotherapy or in combination with iron preparations within a reasonable time ensures the achievement of the target hemoglobin level for subsequent surgical treatment, an acceptable quality of life for patients, and also allows to reduce the risk of perioperative complications and avoid unnecessary blood transfusions.

Iron deficiency anemia has medical and social consequences worldwide, so the treatment of iron deficiency is an important goal. Oral iron therapy may not be optimal in some clinical situations requiring rapid replenishment of iron stores or due to possible ineffectiveness or intolerance. Intravenous iron therapy is an effective method for the treatment of iron deficiency anemia. So far, the use of intravenous iron preparations in pediatric patients has been limited, despite extensive experience of their use in adults and the results of studies conducted with children that have also demonstrated the efficacy and safety of this therapeutic option in pediatric patients. First of all, it is due to concerns about a risk of severe allergic reactions which was quite high in the era of first-generation intravenous iron medicines. The emergence of a new generation of more effective and safer intravenous iron preparations, including high-dose parenteral iron products, makes this type of therapy a promising means of treatment for iron deficiency in children and adolescents.

Iron supplementation has been an important and complicated health topic. Available iron preparations generally have issues such as instability, inadequate absorption, and low consumer acceptability. This study provided a novel ferric pyrophosphate (FePP) delivery system, the FePP-casein-phosphopeptide-dextran (FCD) complex, with sodium pyrophosphate (NaPP) as a solvent promoter and casein-phosphopeptide (CPP) and β-glucan as wall materials. Compared to FePP, FCD showed better properties, including good water solubility (95% resolubilization), color stability (pH 3.5-6.5), compatibility with sensitive nutrients like vitamin C (VC), and lipid oxidation stability (delayed by approximately 50%). In vitro, FCD demonstrated gradual iron release in the gut with a release rate exceeding 80%. In vivo, FCD effectively alleviated iron deficiency anemia (IDA) symptoms in mice, with superior overall efficacy to FePP. Therefore, this novel FCD iron delivery system had considerable potential to be applied in nutritional food systems or iron supplements.

Scalable and cost-effective nanoscale zero-valent iron preparation by combining ball-milling and H2-reduction of micron Fe2O3: modulating crystal plane and reactivity

postpartum hemorrhage is an emergency in obstetrics, which is one of the five most common causes of maternal mortality. Knowledge of all algorithms and protocols for childbirth, providing assistance in the event of an emergency is the key to reducing maternal mortality and delayed negative health consequences for both the mother and the newborn. The aim of the work was to study the protocols and management of postpartum obstetric hemorrhage. Upon hospitalization, the pregnant woman undergoes laboratory and instrumental examination, the doctor assesses the risk group for postpartum obstetric hemorrhage. First pregnancy, 36 weeks. Twin, bichorionic, biamniotic. History of primary infertility. Pregnancy occurred with the use of additional reproductive technologies. According to the results of the examination, moderate preeclampsia, secondary thrombocytopenia were noted. A cesarean section was performed and one of the main points of highly professional care for postpartum hemorrhage is the administration of drugs: a hormonal preparation of the posterior pituitary gland - oxytocin, an agonist of oxytocin receptors - carbetocin, a fibrinolysis inhibitor - tranexamic acid and prostaglandins - misoprostol; to prevent and eliminate hypochromic anemia - iron preparations in accordance with the approved protocol.

Some intravenous iron preparations cause hypophosphatemia mediated by increased fibroblast growth factor 23. This hypophosphatemia lasts for weeks or months and, when administered to pregnant women, could affect fetal tooth mineralization, which starts in the fourth month of pregnancy. The fetus requires increased calcium and phosphate levels to meet the increased demand for bone and tooth mineralization, development, and growth. As bone mineralization is a priority, calcium and phosphate deficiency could be compensated for by impaired primary and permanent tooth mineralization. Since there is an association between calcium and phosphate deficiency and dental dysplasia in X-linked hypophosphatemic rickets, we hypothesize a possible similar association between hypophosphatemia induced by intravenous iron infusion and dental dysplasia. As the long-term clinical impact of maternal hypophosphatemia on the fetus has not yet been investigated, studies are required to examine the effects of maternal hypophosphatemia on the fetus. Close cooperation between obstetricians, pediatric dentists, and pediatricians is essential to study the effect of hypophosphatemia induced by intravenous iron infusion on the primary and permanent tooth maturation and mineralization, growth, and development in children.

Iron deficiency (ID) in children, especially those under five years, has a well-recognized negative impact on development and growth. However, the potential for reversibility with iron supplementation remains debatable. Therefore, we aimed in this double-blind placebo-controlled clinical trial to investigate the effect of the novel iron preparation, Liposomal Iron (LI), on the development and growth of iron-deficient children. For iron deficiency anemia (IDA) and non-anemic iron deficiency (NAID), 433 children aged 6 to 59 months underwent screening. The NAID group was divided into two groups: one group received a placebo, while the interventional group received liposomal iron for four months, as in the IDA group. Then, compared to baseline, efficacy, development, and growth were reevaluated. The NAID interventional group showed significant improvement in developmental total scores compared to the NAID placebo group with a mean difference of +29.57 versus +0.96 (P < 0.001). Furthermore, the final score was notably superior in the NAID interventional group 181.5, compared to the IDA group, 175.0 (P < 0.001). Liposomal iron showed, in addition to good efficacy and tolerability, a favorable impact on the development and growth of iron-deficient children. However, the best results were obtained from early management prior to the onset of anemia (NAID). NAID, though common, is still underappreciated, and evidence about the benefits of giving iron to children before IDA progression is limited. The Ages and Stages Questionnaires is a reliable screening tool for development during the critical first five years of life. Through an interventional clinical trial, LI demonstrated an effective and tolerable alternative for ID treatment, while overcoming the usual adverse effects of conventional iron therapies. Growth and developmental outcomes improved significantly with early detection and treatment of ID with LI during the NAID stage than when the supplement was used after anemia emergence. Conversely, children with NAID who received a placebo showed further deterioration.

Incorporating iron-rich foods into the diet, adequate breast milk intake, and prophylaxis with iron preparations can prevent iron deficiency anemia (IDA) and iron deficiency (ID) in infancy. This study aimed to elucidate the effects of prophylactic iron preparations, adequate breast milk, and iron-rich supplementary food intake on preventing IDA and ID in infancy. This prospective cohort study included 204 children aged 6 to 24 months who were admitted to the general pediatric outpatient clinic. The patients were divided into groups with and without ID and those with and without IDA. The rates of correct prophylaxis use, adequate breast milk intake, and supplementary food intake were compared. In our study, the ID and IDA rates were 53.9% (n = 110) and 34.8% (n = 71). The rate of recommendation for iron prophylaxis in the 204 patients in our study was 95.1% (n = 194). In our study, the rate of prophylactic use among all patients was 66.7% (n = 136). However, the proportion of patients who correctly used prophylaxis in the entire group was 13.7% (n = 28). The most critical risk factor for developing ID and IDA was lack of prophylaxis (P = .001 and odd ratio: 8.115 for ID and odd ratio: 13.364 for IDA). Prophylaxis emerged as the most critical risk factor for the development of ID and IDA in children aged 6 to 24 months. However, the consumption of more iron-rich foods and breastfeeding for the 1st 6 months is a reliable protective measure against ID and IDA, providing reassurance and confidence in the prevention of these conditions.

There is lack of evidence on how disease activity in inflammatory bowel disease influences response to intravenous iron. A single-centre prospective study was conducted to study responses to intravenous iron in ulcerative colitis. Patients with iron deficiency anemia (hemoglobin < 8 g/dL OR < 12 g/dL with intolerance to oral iron or active disease) received protocolized intravenous iron dosing perEuropean Crohn's and Colitis Organisation (ECCO) guidelines. Ferric carboxymaltose (FCM) or iron isomaltoside was used per patient preference. The outcomes were increase in Hb ≥ 2 g/dL, normalization of Hb at four weeks and normalization of iron indices (serum ferritin >100 ng/mL in active and > 30 ng/mL in inactive disease and transferrin saturation > 20%) assessed at four weeks. Thirty-two patients (females = 21 [65.6%], mean age = 32.78 ± 12.65 years, active disease = 17 [53.1%]) received IV iron. Twenty-one received FCM, while 11 received iron isomaltoside. Complete normalization of Hb was seen in seven (41%) in active patientsand nine (60%) in remission groups (p = 0.47). Normalization of iron profile was seen in 11 (64%) and 12 (80%) patients in two groups, respectively (p = 0.32). Secondary objectives of mean change in Hb and iron indices tended towards better response in inactive group, but were not statistically significant except change in transferrin saturation that was better in inactive group (20.8 ± 9.1% and 14.2 ± 8.1%, p = 0.04). FCM was associated with hypophosphatemia in 6/21 (28.5%) patients vs. none in isomaltoside group. The predictive performance for complete hematological response with the reticulocyte hemoglobin and percentage of hypochromic cells was low (area under the receiver operating characteristic [AUROC] of 0.67 and 0.685, respectively). Although there was a tendency towards better response to intravenous iron in those with remission, the findings were not statistically different.Larger studies are needed to provide conclusive evidence. Iron isomaltoside may be preferable over FCM due to risk of hypophosphatemia with the latter.

The aim of this study is to describe anemia in chronic heart failure (CHF) and to evaluate the effectiveness of oral therapy with sucrosomial iron (SiderAL® Forte) in this group. Material and methods. The study included 56 patients with CHF and anemia. Results. Anemia in CHF corresponds to anemia of chronic disease (ACD) with the development of iron deficiency (ID) in 75% of patients. The use of sucrosomial iron leads to a significant increase in hemoglobin and serum ferritin levels, a decrease in the concentration of N-terminal pro-brain natriuretic peptide, an improvement in exercise tolerance, a reduction in the functional class of CHF, and a decrease in mortality over a 2-year follow-up period. Conclusion. The addition of iron preparations with hepcidin-independent absorption to standard CHF therapy shows a significant positive effect across all criteria and can be recommended for this category of patients in routine clinical practice.

When analyzing 171 medical records of patients of the Pirogov Center who underwent open heart surgery (coronary artery bypass grafting, valve replacement) in 2023–2024, it was found that during treatment (the average hospitalization period in a surgical hospital is 10.9±0.6 days), the average hemoglobin concentration decreases to 91.8±2.2 g/l in women and 100.9±2.5 g/l in men. The need for blood transfusion developed in 73.8% of women and 31.8% of men. 28.7% of patients received hardware reinfusion of autologous red blood cells, which in 53% of cases allowed to avoid allogeneic transfusion. 96.5% of patients received tranexamic acid and 22.2% – iron preparations. It is advisable to include the use of blood components, blood salvage and other patient blood management technologies in clinical guidelines and the standard of medical care for adult cardiac surgery patients.

Introduction. In the context of iron deficiency states in women of reproductive age and, as a result during pregnancy, leads to the formation of the gestational complications and negatively perinatal outcomes. The routine screening for the detection of iron deficiency by determining the level of ferritin allows you to formed risk groups in order to carry out timely correction.Aim. To estimate the level and rate of an iron deficiency state in pregnant women in the first trimester.Materials and methods. The study included 401 pregnant women under surveillance in the period from January to June 2023. The main group was 134 patients with a diagnosis of iron deficiency – 33.4% of the total number of examined. The comparison group is represented by 36 pregnant women with the level of serum ferritin 41 – 60 ug/l.Results. The mean age and gestation of patients in the main and control groups were 27.9 (6.1) and 28.7 (6.8) years and 10.7 (1.9) and 10.6 (1.8) weeks, respectively. The serum ferritin level was 20.57 ± 8.83 ug/l in the patients of the main group and was significantly lower compared to the control group 49.74 ± 6.96 ug/l (p = 0.01). Among the patients in the main group, more than 80% had severe absolute iron deficiency (SF concentration &lt; 15 ug/l), detected in 29.1% of women (39/134) and absolute iron deficiency (SF concentration ≥ 15 – &lt; 30 ug/l) – 52.9% of cases (71/134). Features of the observation showed that in the 2nd trimester of pregnancy in patients with iron deficiency, the diagnosis of anemia was detected 2.6 times more often – 31.3% (42/134) compared to the control group.Conclusions. Determination of serum ferritin allows to identify patients with iron deficiency and timely prescribe iron preparations in preventive/therapeutic doses to reduce the frequency of perinatal and maternal complications.

Anemia is a global public health problem, the main cause of which is iron deficiency in the body. The difficulty of enriching the diet with iron is explained by the oxidative nature of iron, which leads to undesirable sensory changes and a decrease in the quality and shelf life of food. The work is devoted to the selection of bioavailable forms of iron, which, when added to food in an appropriate amount, are not rejected by the body. The aim of the work was to study in experiments on laboratory rats the chronic toxicity and effectiveness of the developed dietary supplement “PoliFerVit” in comparison with commercial preparations of iron oxides E172 (Fe2O3 + FeO) and iron sulfate (FeSO4 × 7H2O). The objects of the study were iron (II) sulfate heptahydrate (FeSO4 × 7H2O), a mixture of iron oxides E172 (Fe2O3 + FeO), dietary supplement “PoliFerVit” for use as a source of iron (FeO, Fe2O3, Fe3O4), vitamin C, and dihydroquercetin. In the process of work, a biologically active food additive (dietary supplement) “PoliFerVit” was developed, the iron content in the additive is 136% of the daily requirement. A comparison of the biological activity and chronic toxicity of the dietary supplement “PoliFerVit” and commercial iron preparations showed that all studied objects, when administered daily to laboratory animals for 32 days, did not affect the body weight of animals and their physiological state, and also did not cause changes in the main indicators of the general blood test, in particular, in the leukocyte formula. The revealed dynamics towards an increase in serum iron content when using a mixture of iron oxides (up to 17%) and dietary supplement “PoliFerVit” (up to 22%) indicates similar bioavailability, and the bioavailability of dietary supplement “PoliFerVit” is higher, which is probably due to the nanoscale size of iron particles and the combined composition of the additive. An important advantage of the dietary supplement “PoliFerVit” is a less pronounced negative effect on the antioxidant system, which was expressed in an increase in the superoxide dismutase index to 44%.

Oral iron preparations for iron deficiency anemia have major side effects, such as nausea and vomiting, which are gastrointestinal symptoms widely known to occur with gastrointestinal motility disorders. However, it is unclear whether these symptoms are associated with gastrointestinal motility. This study aimed to explore the correlation between oral iron preparations that cause nausea and vomiting with gastrointestinal motility. Sodium ferrous citrate (SFC), a common ingredient in iron preparations, was used in this study. Gastrointestinal motility in mice was measured using the 13C-octanoic acid breath test to determine gastric emptying and colonic transport capacities using the bead expulsion test. SFC significantly delayed gastric emptying. However, it did not affect the colonic transport capacity. Treatment with the antiemetic palonosetron, a 5-hydroxytryptamine 3 (5-HT3) receptor inhibitor, abolished the gastric evacuation retardation effect of SFC. However, the additive in the SFC formulation, palonosetron alone, did not affect the gastric emptying capacity. These results suggest that iron preparations cause vagal nausea and vomiting in the upper gastrointestinal tract due to chemical stimulation of the gastrointestinal blood with a concomitant reduction in gastric emptying capacity. Knowledge of the association of delayed gastric emptying with the onset of iron-induced nausea is useful for understanding iron-induced adverse effects.

Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract. It includes Crohn's disease (CD) and ulcerative colitis (UC). It occurs with periods of exacerbations and remissions. One of the most common complications of IBD is iron deficiency anemia (IDA). In IBD, iron deficiency anemia (IDA) often occurs concomitantly with anemia of chronic disease, caused by chronic inflammation of the gastrointestinal tract. Disturbance of iron homeostasis in IBD results from inflammation of the intestinal mucosa, which causes increased blood loss from the gastrointestinal tract and poor iron absorption. A key role is played by hepcidin, which, by acting on ferroportin, inhibits iron absorption in the intestines, despite its deficiency. Less common causes of anemia in IBD include vitamin B12 deficiency, folate deficiency, hemolysis, drug-induced aplasia, or liver disease such as primary sclerosing cholangitis. Symptoms of iron deficiency depend on the severity and chronicity of the anemia. Anemia reduces the quality of life of patients, so diagnosis and treatment of iron deficiency anemia in IBD is essential. Regular monitoring of anemia and iron homeostasis is recommended. Tests should be performed at the time of IBD diagnosis, every 3 months in active disease and every 6-12 months in periods of remission. In all patients with IBD, it is necessary to follow an appropriate diet, but also to treat anemia with iron preparations, oral or intravenous. The choice of the method of iron administration, oral or intravenous, depends on the hemoglobin level, IBD activity, and the patient's tolerance to oral preparations. Regular monitoring is essential because anemia in IBD often recurs.

This case report describes a 24-year-old female patient admitted with severe iron deficiency anemia, presenting with generalized weakness, easy fatigability, and decreased appetite. The patient was initially treated with oral iron supplements, intravenous iron sucrose, and blood transfusion. However, the patient developed adverse reactions to both blood transfusions and iron sucrose. Subsequently, ferric carboxymaltose (FCM) was administered, but the patient experienced symptoms suggestive of an anaphylactic reaction, including hypotension, respiratory distress, and decreased oxygen saturation. The FCM dose was reduced and eventually discontinued. The causality assessment for both iron sucrose and FCM was determined to be 'Possible' using the WHO UMC scale and Naranjo scale. This case highlights the rare but potentially life-threatening anaphylactic reactions associated with intravenous iron preparations, emphasizing the need for healthcare providers to remain vigilant during administration and to be prepared to manage such reactions promptly. This study underscores the importance of pharmaceutical care and adherence to administration guidelines to minimize the risks of intravenous iron therapies.